SCHEMBL5501205

SCHEMBL5501205

CC(=O)Nc1ccc(Nc2ncc(-c3ccsc3)cn2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSC P53634 3/20 0.62
CTSL P07711 1/20 0.50
BRAF P15056 1/20 0.48
HDAC1 Q13547 1/20 0.48
FYN P06241 2/20 0.47
POLB P06746 2/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
MAPT P10636 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
MCL1 Q07820 1/20 0.46
PTK2B Q14289 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
PIK3CA P42336 1/20 0.45
PIK3CG P48736 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5494755 0.87 CTSC (0.64) CTSCCTSLFYNPOLBMAPT
SCHEMBL5496471 0.84 CTSC (0.49) CTSCCTSLMEN1KMT2AMAPT
SCHEMBL14342357 0.83 CTSC (0.46) CTSCIKBKETBK1
SCHEMBL5496551 0.81 CTSC (0.44) CTSCCTSLFYNCYP3A4CYP2C9
SCHEMBL5508263 0.81 CHEK2 (0.56) CTSCCTSLJAK2JAK3IKBKE
SCHEMBL5495523 0.81 ALDH1A1 (0.47) CTSCPOLBMEN1KMT2AMAPT
SCHEMBL5495338 0.81 KDM4E (0.47) CTSCMAPTSMN1; SMN2JAK2
SCHEMBL222027 0.81 SMN1; SMN2 (0.68) CTSCHDAC1FYNPOLBMEN1
SCHEMBL5499926 0.80 POLB (0.51) CTSCCTSLHDAC1POLBMEN1
SCHEMBL5502963 0.79 CTSC (0.59) CTSCCTSLCYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070293484-A1 Thiophene Heteroaryl Amines SUGEN, INC. 2007-12-20 US claimed
EP-1753750-A1 THIOPHENE HETEROARYL AMINES Sugen, Inc. (US) 2007-02-21 EP claimed
WO-2005113548-A1 THIOPHENE HETEROARYL AMINES SUGEN, INC. (US) 2005-12-01 WO claimed
US-20070293484-A1 Thiophene Heteroaryl Amines SUGEN, INC. 2007-12-20 US disclosed
US-20070293484-A1 Thiophene Heteroaryl Amines SUGEN, INC. 2007-12-20 US disclosed
US-20070293484-A1 Thiophene Heteroaryl Amines SUGEN, INC. 2007-12-20 US disclosed
EP-1753750-A1 THIOPHENE HETEROARYL AMINES Sugen, Inc. (US) 2007-02-21 EP disclosed
WO-2005113548-A1 THIOPHENE HETEROARYL AMINES SUGEN, INC. (US) 2005-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293484-A1 Thiophene Heteroaryl Amines TTK, CHEK2, ABL1 CTSC 2987/4885CTSL 4370/4885BRAF 113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.